Top

European Radiology

Published in:

01-11-2015 | Breast

Correlation between ¹⁸F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer

Authors: Hye Ryoung Koo, Jeong Seon Park, Keon Wook Kang, Wonshik Han, In Ae Park, Woo Kyung Moon

Published in: European Radiology | Issue 11/2015

Abstract

Objectives

The purpose of this study was to investigate whether a correlation exists between ¹⁸F-fluorodeoxyglucose (FDG) uptake and prognostic factors in triple-negative breast cancer (TNBC).

Methods

Between January 2009 and December 2013, 103 patients (mean age, 50.6 years) with primary TNBC (mean, 2.6 cm; range, 1.0–6.5 cm) underwent ¹⁸F-FDG PET/CT for initial staging. Correlations between maximum standardized uptake value (SUV_max) on PET/CT and prognostic factors including tumour size, nodal status, histological grade, Ki-67 proliferation index, tumour suppressor p53, and ‘basal-like’ markers (epidermal growth factor receptor and CK 5/6) were assessed.

Results

The mean SUV_max of the 103 tumours was 10.94 ± 5.25 (range: 2–32.8). There was a positive correlation between SUV_max and Ki-67 (Spearman’s rho = 0.29, P = 0.003) and tumour size (Spearman’s rho = 0.27, P = 0.006), whereas this relationship was not observed in the nodal status, histological grade, p53 status and ‘basal-like’ phenotypes. In a multivariate regression analysis, Ki-67 (P < 0.001) and tumour size (P = 0.009) were significantly associated with SUV_max in TNBCs.

Conclusions

Increased ¹⁸F-FDG uptake on PET/CT was correlated with a high Ki-67 proliferation index and larger tumour size in TNBC. These results suggest a potential role of ¹⁸F-FDG PET/CT in identifying TNBC with more aggressive behaviour.

Key points

• A wide range of FDG uptake reflected heterogeneity of cancer metabolism.

• FDG uptake was correlated with the Ki-67 proliferation index in TNBC.

• FDG uptake was correlated with tumour size in TNBC.

• FDG uptake was not correlated with ‘basal-like’ phenotype.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed

Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16:1–11CrossRefPubMed

Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:142–150PubMedCentralCrossRefPubMed

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32CrossRefPubMed

Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18:123–133PubMedCentralCrossRefPubMed

Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126CrossRefPubMed

Aukema TS, Rutgers EJ, Vogel WV et al (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36:387–392CrossRefPubMed

Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349CrossRefPubMed

10.

Groheux D, Giacchetti S, Moretti JL et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435CrossRefPubMed

11.

Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112:995–1000CrossRefPubMed

12.

Tchou J, Sonnad SS, Bergey MR et al (2010) Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12:657–662CrossRefPubMed

13.

Koo HR, Park JS, Kang KW et al (2014) 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24:610–618CrossRefPubMed

14.

Groheux D, Hindie E, Giacchetti S et al (2012) Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed

15.

Ohara M, Shigematsu H, Tsutani Y et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: usefulness for malignant grade of triple-negative breast cancer. Breast 22:958–963CrossRefPubMed

16.

Mountz JM, Yankeelov TE, Rubin DL et al (2014) Letter to cancer center directors: progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. J Clin Oncol 32:2115–2116CrossRefPubMed

17.

Mankoff DA, Pryma DA, Clark AS (2014) Molecular imaging biomarkers for oncology clinical trials. J Nucl Med 55:525–528CrossRefPubMed

18.

Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCentralCrossRefPubMed

19.

Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed

20.

Zabaglo L, Salter J, Anderson H et al (2010) Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 63:800–804CrossRefPubMed

21.

Zellars RC, Hilsenbeck SG, Clark GM et al (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906–1913PubMed

22.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed

23.

Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376CrossRefPubMed

24.

Gerdes J, Li L, Schlueter C et al (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867–873PubMedCentralPubMed

25.

Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552PubMedCentralCrossRefPubMed

26.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCentralCrossRefPubMed

27.

Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCentralCrossRefPubMed

28.

Zhang G, Xie W, Liu Z et al (2014) Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori 100:136–142PubMed

29.

Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220CrossRefPubMed

30.

Polley MY, Leung SC, McShane LM et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897–1906PubMedCentralCrossRefPubMed

31.

Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767PubMedCentralCrossRefPubMed

32.

Kim S, Kim do H, Jung WH, Koo JS (2013) Metabolic phenotypes in triple-negative breast cancer. Tumour Biol 34:1699–1712CrossRefPubMed

33.

Uematsu T, Kasami M, Yuen S (2009) Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer 16:97–104CrossRefPubMed

34.

Kim JY, Lee SH, Kim S, Kang T, Bae YT (2015) Tumour 18F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol 25:1172–1181CrossRefPubMed

35.

Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N (2009) Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96:166–170CrossRefPubMed

36.

Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323CrossRefPubMed

37.

Silwal-Pandit L, Vollan HK, Chin SF et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20:3569–3580CrossRefPubMed

38.

Soussan M, Orlhac F, Boubaya M et al (2014) Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One 9:e94017PubMedCentralCrossRefPubMed

Title: Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer
Authors: Hye Ryoung Koo
Jeong Seon Park
Keon Wook Kang
Wonshik Han
In Ae Park
Woo Kyung Moon
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 11/2015
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3734-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Correlation between ¹⁸F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer

Abstract

Objectives

Methods

Results

Conclusions

Key points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key points

Please log in to get access to this content

Other articles of this Issue 11/2015

Hyperintense acute reperfusion marker is associated with higher contrast agent dosage in acute ischaemic stroke

Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol

Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experience

Grading of Crohn’s disease activity using CT, MRI, US and scintigraphy: a meta-analysis

Cohort study of lumbar percutaneous chemonucleolysis using ethanol gel in sciatica refractory to conservative treatment

Paediatric CT dose: a multicentre audit of subspecialty practice in Australia and New Zealand